I agree. Nothing has happened yet. I always thought this was a clean shot to $2 on even a so-so deal.(my guess was (zio-201)the prime billing for zio-101 @ asco sets up the potential we will have 2 funded late stage programs running by year end. That becomes a whole other valuation metric.
mark, the article you sent to me on zio-101 is interesting. It appears the drug works via a different pathway from arsenic trioxide and (potentially) has a much lower tox profile.i am betting the asco news both is surprising and good.